MSF Access Campaign

14/07/2025

MSF welcomes World Health Organization (WHO)’s new guidelines for lenacapavir, a game-changing prevention drug. But we’re deeply concerned about restricted access due to Gilead’s licensing limitation.

“Lenacapavir is the kind of innovation that can be transformative, but only if it is ultimately accessible to communities in low- and middle-income countries that most need it,” says Antonio Flores, Senior HIV/TB Advisor for MSF Southern Africa Medical Unit (SAMU).

New drug Lenacapavir is an HIV prevention tool which offers greater choice and longer protection, and high effectiveness for people wishing to protect themselves from acquiring HIV through a twice-yearly injection.

10/07/2025

People with in the EU/EEA region continue to face delayed or outdated access to treatment due to the unavailability, high price and fragmented supply of TB medicines. Read our policy brief that outlines barriers to accessing TB medicines, highlights regulatory and procurement pathways and flexibilities enshrined in EU legislation, and provides urgent recommendations for the region.

MSF policy brief outlining barriers to accessing TB medicines in the EU/EEA region and recommendations to overcome them.

13/06/2025

Insulin pens must be affordable and available for all people with who need them. Why? For many people with diabetes, using pens to administer insulin is easier, more accurate, and preferred over more difficult-to-use vials and syringes.

So, while we welcome the news that Novo Nordisk will supply South Africa with analogue insulin pens, the price is too high.

All insulin pens should be $1 per pen so that more people with diabetes can access their preferred insulin delivery device.

https://msfaccess.org/msf-welcomes-novo-nordisks-commitment-supply-south-africa-analogue-insulin-pens-price-must-come

12/06/2025

We welcome the news that Novo Nordisk will supply South Africa with analogue insulin pens, but the price Novo Nordisk is charging per pen is too high at $3.95 per pen.

We’re calling for all insulin pens to be available at $1 per pen, so that everyone can access the highest standard of diabetes treatment, especially as their cost of production is estimated to be as low as $0.94 per pen, including a profit.

Novo Nordisk starts supply of analogue insulin pens to South Africa but price remains high still. All insulin pens must be available at $1 per pen.

28/05/2025

MSF took the floor at World Health Organization (WHO) World Health Assembly. Our statements included calls for Member States to implement the new Pandemic Agreement, and to prioritise universal access to care for diabetes, mental health conditions, and cervical cancer.

Read more:

MSF statements at the 78th session of the World Health Assembly (WHA) 19–27 May 2025.

15/05/2025

⚠️South Africa: Lifesaving scientific research on prevention, testing, treatment and care for people living with and is under serious threat due to funding suspensions and grant terminations U.S. government.

TAG and MSF urge donors to act now to protect ongoing research and ensure continuity of care for people with HIV and TB

28/04/2025

Every child should be able to be protected from vaccine-preventable diseases. However, various logistical barriers mean that vaccines often don’t reach everyone who needs them, especially children living in conflict zones, refugee camps, and hard-to-reach areas.

During hashtag , we share what needs to happen to make sure vaccines reach children everywhere, including how an ambitiously funded Gavi, the Vaccine Alliance can help make this happen.

For the full story, read: “A shot at life: how to reach more children in humanitarian settings with lifesaving vaccination,” by MSF’s Victorine de Milliano and Pamela Onango in Health Policy Watch: https://healthpolicy-watch.news/a-shot-at-life-how-to.../

28/04/2025

Every child should be able to be protected from vaccine-preventable diseases. However, various logistical barriers mean that vaccines often don’t reach everyone who needs them, especially children living in conflict zones, refugee camps, and hard-to-reach areas.

During hashtag , we share what needs to happen to make sure vaccines reach children everywhere, including how an ambitiously funded Gavi, the Vaccine Alliance can help make this happen.

For the full story, read: “A shot at life: how to reach more children in humanitarian settings with lifesaving vaccination,” by MSF’s Victorine de Milliano and Pamela Onango in Health Policy Watch : https://healthpolicy-watch.news/a-shot-at-life-how-to-reach-more-children-in-humanitarian-settings-with-lifesaving-vaccination/

24/04/2025

We published the costs of TB-PRACTECAL, a clinical trial conducted to identify a shorter, all-oral treatment for drug-resistant tuberculosis (DR-TB): https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0003759

15/04/2025

After more than three years of intense deliberations on the Pandemic Agreement at the World Health Organization (WHO), countries are expected to conclude the negotiations today.

The bottom line 👉

As Pandemic Agreement negotiations may conclude today, MSF welcomes the inclusion of positive elements facilitating more equitable response to future health emergencies.

20/03/2025

Ahead of , we’re sounding the alarm!

Children are at the highest risk of developing . The WHO estimates that every year around 1.25 million children (0-14 yrs) fall ill with TB, but ONLY HALF are diagnosed and treated.

With recent international funding cuts undermining continuity in TB care in places where we work, we are incredibly concerned about the impact on children, who are the most vulnerable.

That’s why were urgently calling for all countries and international donors to step up and ensure that there is sustained funding for TB care for all, especially for young children.

It’s time to end TB, a preventable, curable disease but still the leading infectious disease killer in the world.

https://msfaccess.org/msf-calls-sustained-investments-fight-against-tuberculosis-children

22/11/2024

Living with is challenging, no matter where you live. Now imagine being on the move, seeking safety for you and your family, with little or no access to treatment.

Watch our story series, , featuring 3 refugees who have faced insulin shortages and difficult journeys while managing diabetes.

Ghassan has type 2 . He managed it with a strict treatment routine for 15+ years. However, when he and his family left Gaza in September 2023, to se...